The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 142 of 170 of this archive, newest first.
Reported from the sessions, and from the two hours afterwards.
We give background rates alongside trial rates, because an event occurring during treatment is not thereby caused by it.
Duplicate submissions under different names test within-laboratory repeatability, which is a different quantity from between-laboratory reproducibility.
Follow the resin, not the catalogue.
Reported from the analysis, not from a warning notice.
The evidence base is thin and the document says so, which is to its credit.
Reported from the sessions, and from the two hours afterwards.
Storage instructions in this market are close to uniform and almost never accompanied by the study that would justify them. Uniformity is a sign of convention, not of…
Three different explanations for the same abnormal number, and how to tell them apart.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Reported from the analysis, not from a warning notice.
The observation that closes a facility is rarely the dramatic one.
The evidence base is thin and the document says so, which is to its credit.
The purity figure is the least informative line on a well-constructed certificate and the only line most buyers read.
The features that should prompt urgent assessment, stated once and plainly.
Reducing a dose is not going backwards. In a tolerability-limited class it is the mechanism by which the ceiling is found.
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Efficacy was never the question in this appraisal. Duration of treatment was.
A proper account of an operation that existed, and of what closing it cost.
The document is four pages. Three of them are about dates.
We describe each pathway in enough chemical detail to explain why it is invisible to the method the trade uses, because that is the part which has practical consequences.
The route did not close because of a rule about peptides.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Efficacy was never the question in this appraisal. Duration of treatment was.
What a laboratory can and cannot know about the provenance, storage history and representativeness of what lands on its bench.
Where the familiar figures come from, what populations they were measured in, and how far the extrapolation reaches.
The evidence base is thin and the document says so, which is to its credit.
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Reported from the analysis, not from a warning notice.
Reported from the sessions, and from the two hours afterwards.